Feedback
Settings

Settings

Goto Application

1,739 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

PUBLICATION_DATE=2009
1 / 174
1.2009515523ＴＮＦスーパーファミリー受容体に対するスプライス切替オリゴマーならびに該オリゴマーを含む医薬組成物
JP - 16.04.2009
Int.Class C12N 15/09
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
 Appl.No 2008540193 Applicant サンタリス　ファーマ　アー／エス Inventor サザニ、　ペーター　エル．

ＴＮＦ受容体（ＴＮＦＲ１およびＴＮＦＲ２）ならびにＴＮＦＲスーパーファミリーのその他の受容体の発現を、これらの受容体をコードする前駆体ｍＲＮＡのスプライシングを調整する化合物を使用して制御するための、方法および組成物が開示される。より具体的には、これらの化合物により上記受容体の膜貫通ドメインが除去され、ＴＮＦ−α活性または関連リガンドの活性を低減するアンタゴニストとして作用する可溶性の受容体が生じる。ＴＮＦ−α活性を低減することにより、ＴＮＦ−α活性に関連した炎症性の疾病または状態を治療または改善する方法が提供される。同様に、他のリガンドに関連した疾病も類似の方法で治療することができる。特に、本発明の化合物は、インビボにおいて安定で、ＲＮＡに配列特異的にハイブリダイズし、かつその標的と共にＲＮａｓｅＨによる分解を受けない小さな分子である、スプライス−スプライス切替オリゴマー（ＳＳＯ）である。

2.2009167146CLEANSING COSMETIC COMPOSITION
JP - 30.07.2009
Int.Class A61K 8/37
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
33containing oxygen
37Esters of carboxylic acids
 Appl.No 2008009846 Applicant KOBAYASHI PHARMACEUT CO LTD Inventor ITO MARE

PROBLEM TO BE SOLVED: To provide a lamella crystal-type cleansing cosmetic composition excellent in the cleansing power for and the rinsability of messy makeup, and good in stability of withstanding its own long-term storage.

SOLUTION: The cosmetic composition, having a lamella liquid crystalline structure, comprises a component A as polyglyceryl mono- or dioleate, a component B as polyglyceryl mono- or diisostearate, water, and an oily component.

COPYRIGHT: (C)2009,JPO&INPIT

3.101421274Process for the production of anhydrosugar alcohols
CN - 29.04.2009
Int.Class C07D 493/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
493Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02in which the condensed system contains two hetero rings
06Peri-condensed systems
 Appl.No 200780013774.6 Applicant Archer-daniels-midland Company Inventor Sanborn Alexandra J.
A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.
4.02372401EUKARYOTIC HOST CELL FOR EXPRESSION VITAMIN K DEPENDENT PROTEIN, EXPRESSION VECTOR IN EUKARYOTIC CELLS, METHOD FOR MAKING GAMMA-CARBOXYLATED VITAMIN K DEPENDENT PROTEIN AND METHOD FOR MAKING PHARMACEUTICAL COMPOSITION FOR COAGULATION INDUCTION OR STIMULATION OF COAGULATION INCREASE OR DECREASE
RU - 10.11.2009
Int.Class C12N 15/63
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
 Appl.No 2006110147/13 Applicant Inventor ФЕНГЕ Кристель (SE)
FIELD: medicine. SUBSTANCE: vitamin K dependent protein is made by separating a cultivated eukaryotic cell that contains an expressing vector that contains a nucleic acid molecule coding vitamin K dependent protein and associated sequences regulating expression. The associated sequences contain the first promoter and the nucleic acid molecule coding gamma-glutamylcarboxylase, and the second promoter. The first promoter represents a pre-early promoter of human cytomegalovirus (hCMV), and the second promoter is a pre-early promoter SV40. Herewith the expressing relation of vitamin K dependent protein and gamma-glutamylcarboxylase is 10:1 to 250:1. EFFECT: invention allows for making gamma-carboxylated vitamin K dependent protein in production quantities. 29 cl, 5 dwg, 6 tbl, 7 ex
5.1020090051209APPLES WITH HIGH POLYPHENOLIC CONTENT
KR - 21.05.2009
Int.Class A23L 1/30
AHUMAN NECESSITIES
23FOODS OR FOODSTUFFS; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES
LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D91; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
1Foods or foodstuffs; Their preparation or treatment
29Modifying nutritive qualities of foods; Dietetic products
30containing additives
 Appl.No 1020097004936 Applicant CORESSENCE LIMITED Inventor WOOD RICHARD
The invention relates to apples comprising high concentrations of polyphenols, to processes for obtaining said apples and to uses of apples as a method of treatment or prophylaxis of cardiovascular disease, colon cancer and digestive health. ©KIPO&WIPO 2009
6.2011508USE OF TRAP PROTEIN PER SE AS ACTIVE INGREDIENT FOR MANUFACTURING A MEDICAMENT FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTION
EP - 07.01.2009
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No 07720819 Applicant HAINAN GT UNIPUL PHARMACEUTICAL CO LTD Inventor YANG GUANG
The present invention discloses the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament comprising TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins of the present invention is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.
7.20090305975Use of Trap Protein Per se as an Active Ingredient for the Manufacture of a Medicament for the Treatment of Staphylococcus Aureus Infection
US - 10.12.2009
Int.Class A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
 Appl.No 12226491 Applicant Inventor Yang Guang

Disclosed herein is the use of TRAP per se as an active ingredient for the manufacture of a medicament for the treatment of Staphylococcus aureus infection. An exogenous TRAP (native TRAP or recombinant TRAP) per se can effectively inhibit the production of Staphylococcus aureus exotoxins, thereby reducing the pathogenicity of Staphylococcus aureus. In addition, a medicament including TRAP also stimulates the production of corresponding antibodies in human body at the time when it is used to treat Staphylococcus aureus infections, and these antibodies can further inhibit the production of Staphylococcus aureus exotoxins. Such double actions increase the effects of medicament and provide a novel medicament action mode. Moreover, since TRAP functions merely to the toxicity of bacteria but does not affect the growth of bacteria, it cannot make bacteria readily develop drug resistance, and also effective to drug resistant Staphylococcus aureus. Moreover, no homologous sequence of the TRAP proteins is found in human genome, so that the medicaments of TRAP cannot cause human immunologic diseases.

8.2009120527SKIN CARE PREPARATION FOR EXTERNAL USE
JP - 04.06.2009
Int.Class A61K 8/33
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
8Cosmetics or similar toilet preparations
18characterised by the composition
30containing organic compounds
33containing oxygen
 Appl.No 2007295837 Applicant SHISEIDO CO LTD Inventor MORI YUICHIRO

PROBLEM TO BE SOLVED: To provide a humectant having an extremely excellent moisture retaining effect and fresh and youthful sense of use (sense of moisture retaining effect) and a skin care preparation for external use.

SOLUTION: The humectant comprises one or more selected from a lower alkyl pentitol ether represented by formula (I) [wherein A is a pentitol residue after the removal of m hydrogen atoms; R is a 1-4C alkyl group (including a hydroxyalkyl group); and m is an average substitution degree for R and a number of 1-5] and a lower alkyl hexitol ether represented by formula (II) [wherein B is a hexitol residue after removal of n hydrogen atoms; R is a 1-4C alkyl group (including a hydroxyalkyl group); and n is an average substitution degree for R and a number of 1-6]. The skin care preparation for external use comprises the humectant.

COPYRIGHT: (C)2009,JPO&INPIT

9.WO/2009/035541METHOD OF TREATING INHERITED SEVERE NEUTROPENIA
WO - 19.03.2009
Int.Class A01N 43/62
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
43Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
48having rings with two nitrogen atoms as the only ring hetero atoms
62three- or four-membered rings or rings with more than six members
 Appl.No PCT/US2008/010430 Applicant MERCK SHARP & DOHME CORP. Inventor DALE, David, C.
The invention is directed to a method of treating severe neutropenia, and in particular, cyclic neutropenia (CN) or severe congenital neutropenia (SCN), in a patient in need of such treatment comprising: administering a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
10.20090260092METHODS OF DIAGNOSING ALZHEIMER'S DISEASE AND MARKERS IDENTIFIED BY SET ASSOCIATION
US - 15.10.2009
Int.Class A01K 67/027
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67Rearing or breeding animals, not otherwise provided for; New breeds of animals
027New breeds of vertebrates
 Appl.No 12487608 Applicant Translational Genomics Research Institute Inventor STEPHAN Dietrich A.

The present disclosure relates to genetic markers and methods of diagnosing and screening for late-onset Alzheimer's disease (LOAD). As such, the disclosure encompasses a whole-genome association analysis of single nucleotide polymorphisms (SNPs) of which a number are located within the GRB2-associated binding protein 2 (GAB2) gene as well as other markers associated with other genes. The disclosure identifies two novel haplotypes within the GAB2 gene, i.e., a LOAD risk-enhancing and a LOAD risk-decreasing haplotype. These haplotypes modify LOAD risk differentially in combination with APOE alleles. Further encompassed are therapeutic methods and agents of decreasing the deterioration of cells associated with LOAD.

# -